How does tirzepatide work?

How Tirzepatide Works

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite through activation of both incretin hormone pathways. 1

Dual Receptor Mechanism

Tirzepatide functions as a "twincretin" by simultaneously activating two distinct receptor systems 2:

• GIP receptor activation: Tirzepatide is structurally derived from human GIP hormone and binds to GIP receptors with high affinity
• GLP-1 receptor activation: The molecule has approximately five times less affinity for GLP-1 receptors compared to endogenous GLP-1, but still produces robust therapeutic effects 1

This dual agonism represents a novel approach, as GIP was previously thought to have limited therapeutic potential until tirzepatide's development 1.

Pancreatic Effects on Glucose Control

The medication works through glucose-dependent mechanisms in the pancreatic islets:

Beta cells (insulin secretion):

• GLP-1 and GIP receptor activation increases intracellular calcium in beta cells
• This triggers insulin exocytosis in response to elevated postprandial glucose
• Insulin secretion is significantly attenuated when glucose levels are normal, explaining the low hypoglycemia risk 1
• May promote beta cell proliferation and protect against apoptosis 1

Alpha cells (glucagon regulation):

• GLP-1 receptor activation inhibits glucagon secretion
• GIP receptor activation has context-dependent effects: augments glucagon during euglycemia/hypoglycemia but inhibits it during hyperglycemia 1
• Only 10-15% of alpha cells express GLP-1 receptors, while GIP receptors are more widely distributed 1

Gastrointestinal Effects

Much of tirzepatide's glucose-lowering effect comes from delayed gastric emptying rather than pancreatic effects alone 1:

• Inhibits gastric peristalsis while increasing pyloric tone
• This delay is more pronounced in individuals with normally rapid gastric emptying 1
• The mechanism is mediated through vagus nerve pathways 1
• Slowed gastric emptying reduces postprandial glucose spikes, as gastric emptying is the primary determinant of postprandial glycemic response 1

Weight Loss Mechanisms

Tirzepatide produces superior weight loss (15-20% body weight reduction) compared to selective GLP-1 receptor agonists 3:

• Reduces appetite and increases satiety
• Creates feelings of abdominal fullness
• Recent evidence suggests the weight loss effect specifically requires leptin receptor signaling in adipose tissue 4
• The dual GIP/GLP-1 mechanism appears to enhance weight reduction beyond what GLP-1 agonism alone achieves 3

Molecular Modifications for Prolonged Action

The molecule has been engineered to resist rapid degradation:

• Modified to prevent cleavage by dipeptidyl peptidase-4 enzyme (which normally inactivates native GLP-1 within 2 minutes) 1
• Contains a C20 fatty diacid moiety attached via a linker, allowing for once-weekly subcutaneous administration 5
• These modifications extend the elimination half-life substantially compared to endogenous incretins 1

Additional Metabolic Effects

Beyond glucose and weight control, tirzepatide improves:

• Insulin sensitivity (to a greater extent than selective GLP-1 agonists)
• Lipid profiles: reduces LDL cholesterol and triglycerides 6
• Blood pressure 6
• Reduces prandial insulin and glucagon concentrations more effectively than semaglutide 7

Clinical Context

The superior efficacy of tirzepatide over selective GLP-1 receptor agonists in clinical trials (SURPASS 1-5) demonstrates that the addition of GIP receptor agonism provides meaningful therapeutic advantages 7. In head-to-head comparisons, tirzepatide produced greater HbA1c reductions (1.24-2.58%) and weight loss (5.4-11.7 kg) than semaglutide 1.0 mg weekly 7, with 23-62% of patients achieving normoglycemia (HbA1c <5.7%) 8.

The mechanism by which GIP contributes to these enhanced effects remains an area of active investigation, as previous studies suggested type 2 diabetes patients were unresponsive to GIP 7. The synergistic effects of dual incretin agonism appear to improve both insulin secretion and insulin sensitivity beyond what either pathway achieves independently 7.